

Correction

Correction: Pre-clinical validation of B cell maturation antigen (BCMA) as a target for T cell immunotherapy of multiple myeloma

De-Xiu Bu^{1,*}, Reshma Singh^{1,*}, Eugene E. Choi^{1,*}, Marco Ruella³, Selene Nunez-Cruz³, Keith G. Mansfield¹, Paul Bennett¹, Nathaniel Barton¹, Qilong Wu², Jiquan Zhang², Yongqiang Wang², Lai Wei², Shawn Cogan¹, Tucker Ezell¹, Shree Joshi¹, Kellie J. Latimer¹, Brian Granda¹, William R. Tschantz¹, Regina M. Young³, Heather A. Huet¹, Celeste J. Richardson¹ and Michael C. Milone^{3,4}

¹Novartis Institutes for Biomedical Research, Cambridge, MA 02139, USA

²China Novartis Institutes for Biomedical Research, Shanghai 201203, China

³Center for Cellular Immunotherapies, Perelman School of Medicine at the University of Pennsylvania, Philadelphia, PA 19104, USA

⁴Department of Pathology and Laboratory Medicine, Perelman School of Medicine at the University of Pennsylvania, Philadelphia, PA 19104, USA

*These authors have contributed equally to this work

Published:

Copyright: © 2021 Bu et al. This is an open access article distributed under the terms of the [Creative Commons Attribution License](#) (CC BY 3.0), which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.

This article has been corrected: Additional information for Supplementary Table 1 was accidentally omitted from the published article. The additions to Table 1 now appear below. The authors declare that these corrections do not change the results or conclusions of this paper.

Original article: Oncotarget. 2018; 9:25764–25780. <https://doi.org/10.18632/oncotarget.25359>

Supplementary Table 1: List of the antibodies used for multiparametric flow cytometry

Specificity	Fluorochrome	Clone	Vendor	cat #
CD14	V500	M5E2	BD Horizon	561391
CD19	PE-Cy7	SJ25C1	eBioscience	25-0198-42
CD3	PE	OKT3	eBioscience	12-0037-42
CD45	BV421	HI30	Biologend	304032
CD8	PE-Cy7	RPA-T8	eBioscience	25-0088-42
CD38	APCeF780	HIT2	eBioscience	47-0389-42
BCMA	PE		R&D Systems	FAB193P
BCMA	PE	19F2	Biologend	357504
CD56	BV605	HCD56	Biologend	318333
Kappa Light C	FITC	TB28-2	eBioscience	11-9970-42
LambdaLight C	PerCPef710	1.155.2	eBioscience	46-9990-42
CD34	APC	581	Biologend	343510
CD45-RA	APC-Cy7	HI100	eBioscience	47-0458-42
Lineage	FITC		eBioscience	22-7778-72
CD90	PerCPCy5.5	eBio5E10	eBioscience	45-0909-41
CD10	BV421	HI10a	Biologend	312218
CD38	PECY7	HIT2	eBioscience	25-0389-42

Multiparametric flow cytometry. Anti-human –mouse antibodies were purchased from multiple vendors (listed in Supplementary Table 1). Cells were washed once in PBS (Gibco, Life Technologies, 14190-136), supplemented with 2% fetal bovine serum (Gemini, 100-106, West Sacramento, CA, USA) and stained for 15 minutes at room temperature. For intracellular staining the Fix&Perm Invitrogen Kit was used according to standard protocol. In all analyses, the population of interest was gated based on forward vs. side scatter characteristics followed by singlet gating, and live cells were gated using Live Dead Fixable Aqua (Invitrogen, LifeTechnologies, L34957). Time gating was included for quality control. Flow cytometry was performed on a four-laser Fortessa-LSR II cytometer or Accuri C6 (Becton-Dickinson, San Jose, CA, USA) and analyzed with FlowJo X 10.0.7r2 (Tree Star, Ashland OR, USA).